Updated

Scientists testing a new experimental drug for mesothelioma, an aggressive asbestos-linked cancer, found it works by disabling PRX3, an antioxidant defense tumors rely on to survive oxidative stress. In an early clinical trial, the drug controlled disease progression in 67% of patients and produced encouraging survival results, raising hope the strategy could extend to other cancers.